+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Revatio

  • ID: 4775234
  • Report
  • 16 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Revatio (sildenafil; Pfizer) is a selective inhibitor of the PDE5 enzyme, which enhances the effect of the endogenous vasodilator, nitric oxide. The extracellular vasodilator NO activates cellular guanylate cyclase, which in turn increases cyclic guanosine monophosphate concentrations, leading to smooth muscle cell vasorelaxation.

Analyst Outlook
The first-to-market phosphodiesterase 5 (PDE5) inhibitor Revatio (sildenafil; Pfizer) is firmly established within the treatment algorithm as a first-line treatment for pulmonary arterial hypertension (PAH) patients. However, its loss of exclusivity in the US and EU has resulted in much-reduced sales for Pfizer. Further generic erosion in Japan is also expected from Q3 2018. Nevertheless, Revatio is likely to continue to provide a steady, albeit small, revenue stream for Pfizer, especially as physicians increasingly use combination therapies for their pulmonary hypertension (PH) patients.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Revatio : Pulmonary hypertension

LIST OF FIGURES
Figure 1: Revatio for pulmonary hypertension – SWOT analysis
Figure 2: The authors drug assessment summary of Revatio for pulmonary hypertension
Figure 3: The authors drug assessment summary of Revatio for pulmonary hypertension
Figure 4: Revatio sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25

LIST OF TABLES
Table 1: Revatio drug profile
Table 2: Revatio pivotal trial data in pulmonary hypertension
Table 3: Revatio sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll